| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 | 352 | 394 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 | 69 | 97 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % | 18 % | 23 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 | 7 | 16 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 | 29 | 45 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.69 | 8.70 |
Metropolis Healthcare
Metropolis Healthcare
2,121.30
-4.30
(-0.20%)
Market Cap
10,988.70 Cr
EPS
28.29
PE Ratio
72.21
Dividend Yield
0.00 %
Industry
Healthcare Services52 Week High
2,318.30
52 Week Low
1,315.00
PB Ratio
8.30
Debt to Equity
0.17
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
Company News
View All News
Metropolis Healthcare Reports 23% Revenue Growth in Q1 FY26, Driven by Organic Growth and Acquisitions3 days ago
Metropolis Healthcare Limited reported 23% revenue growth for Q1 FY26, with organic business growing 13.2% driven by volumes and improved realizations. The company achieved 24.7% EBITDA margin on organic basis, up 40 basis points sequentially. Patient volumes grew 7% organically to 3.2 million, while B2C revenue increased 16% year-on-year. The company is integrating three recent acquisitions - Core Diagnostics, DAPIC Dehradun, and Scientific Pathology Agra. Core Diagnostics turned EBITDA positive with low single-digit margins, improving from breakeven levels. Metropolis announced acquisition of Ambika Diagnostics in Kolhapur for Rs.17 crores. The company expanded basic radiology services to 20 locations with full services and 240 locations offering ECG. TruHealth preventive portfolio now contributes 18% of overall revenue, growing 22% year-on-year. North region contribution increased to 17% of total revenue, largely due to Core Diagnostics integration. The company added 80 new collection centers in Q1 and plans to add 400+ centers this year, expanding presence from 750 to 1,000 towns.
Metropolis Healthcare Completes 25th AGM with Strong Shareholder Approval Across All Resolutions3 days ago
Metropolis Healthcare Limited held its 25th Annual General Meeting on August 13, 2025, via video conferencing. The company achieved high voter participation with 91.65% of outstanding shares participating in the voting process. All 11 resolutions were approved, including adoption of audited financial statements for the year ended March 31, 2025, re-appointment of directors Hemant Sachdev and Ameera Shah, and ratification of cost auditor remuneration. Key approvals included Ameera Shah's re-appointment as Chairperson & Whole-time Director (99.77% approval), approval of remuneration for Dr. Sushil Shah as Non-Executive Non-Independent Director (86.78% approval), and appointment of secretarial auditors. The company also approved two new employee stock option plans - the Metropolis Employees Stock Options Plan 2025 and Restrictive Stock Units Plan 2025, along with their extension to subsidiary employees. Promoter and promoter group shareholders showed unanimous support across all resolutions with 100% approval rates. The scrutinizer's report was prepared by Vijay Yadav of AVS & Associates Company Secretaries.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,347.80 | #1 28,046.40 | 54.69 | #1 2,554.80 | 11.28 | #1 492 | 24.30 | 74.85 | |
2,121.30 | #2 10,988.70 | #9 72.21 | #2 1,346.30 | #9 10.64 | #3 146 | #6 18.90 | 66.87 | |
1,053.20 | 10,815.00 | 71.76 | 681.39 | 20.11 | 152 | 22.54 | 51.11 | |
1,383.70 | 7,332.80 | 69.01 | 702.20 | 20.80 | 91 | 60.25 | 71.82 | |
790.20 | 2,551.50 | 31.96 | 717.16 | 25.65 | 81 | 14.53 | 42.78 | |
302.30 | 1,574.40 | 47.26 | 255.90 | 15.11 | 31 | 19.48 | 45.17 | |
1,660.00 | 1,420.80 | 29.82 | 96.47 | 25.47 | 49 | 11.50 | 62.76 | |
271.55 | 863.80 | #1 9.41 | 1,110.95 | 35.04 | -197 | -35.12 | 41.82 | |
281.50 | 550.10 | 30.20 | 147.04 | #1 248.07 | 18 | #1 444.44 | 59.43 | |
213.65 | 148.80 | 97.56 | 41.78 | 6.34 | 1 | 0.00 | 72.47 |
Forecast
Actual
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
13.23 %
Cash Flow Change
-0.50 %
ROE
-6.76 %
ROCE
-11.55 %
EBITDA Margin (Avg.)
-1.42 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 | 346 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 | 349 |
| Total Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 | 294 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 | 238 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 | 1,335 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,078 | 1,313 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % | 48.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % | 12.83 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % | 32.40 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % | 4.16 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % | 1.72 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 | 50,015 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.03 | 0.36 | 0.39 | 0.67 | 0.46 | 0.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Aug 2025 |  Annual General Meeting | NA | 13 Aug 2025 | 1,938.80 | 2,092.90 |
| 07 Aug 2025 |  Quarterly Result Announcement | NA | 07 Aug 2025 | 2,019.00 | 2,055.70 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,694.80 | 1,712.30 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,708.90 | 1,757.75 |
| 08 Nov 2024 | Quarterly Result Announcement | NA | 08 Nov 2024 | 2,119.10 | 2,112.60 |
| 21 Aug 2024 | Annual General Meeting | NA | 21 Aug 2024 | 2,098.30 | 2,091.55 |
| 17 Nov 2023 |  Dividend | ₹ 4.00 /share | 17 Nov 2023 | 1,472.25 | 1,606.85 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 1,289.35 | 1,348.60 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 2,459.95 | 1,976.10 |
| 19 Feb 2021 | Dividend | ₹ 8.00 /share | 17 Feb 2021 | 2,163.55 | 2,011.85 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
3 days ago
3 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report3 days ago
3 days agoShareholder Meeting / Postal Ballot-Outcome of AGM4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoUpdate On Schedule Of Earnings Conference Call For The Quarter Ended June 30 202510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Acquisition10 days ago
10 days agoUnaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 202510 days ago
10 days agoBoard Meeting Outcome for The Meeting Held Today (August 07 2025)10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Letter To Shareholders Containing Weblink Of 25Th Annual General Meeting And Annual Report For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 25Th Annual General Meeting For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Disclosure Under Regulation 30 Of Listing RegulationsJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 08, 2025
Jul 08, 2025Business Update For Q1FY26Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 04, 2025
Jul 04, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 02, 2025
Jul 02, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 18, 2025
Jun 18, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 18 2025Jun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 17, 2025
Jun 17, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 16, 2025
Jun 16, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Jun 03, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Jun 03, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 03 2025Jun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 24, 2025
May 24, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
May 13, 2025Technical Indicators
RSI(14)
Neutral 66.87
ATR(14)
Less Volatile 63.99
STOCH(9,6)
Neutral 71.58
STOCH RSI(14)
Overbought 87.54
MACD(12,26)
Bullish 2.84
ADX(14)
Strong Trend 45.80
UO(9)
Bearish 55.92
ROC(12)
Uptrend And Accelerating 8.77
WillR(14)
Overbought -16.62
Mutual Fund Holdings
Tata Multicap Fund Direct - Growth 
Kotak Balanced Advantage Fund Direct - Growth 
Canara Robeco Small Cap Fund Direct - Growth 
Templeton India Value Fund Direct Plan-Growth 
UTI Value Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth 
JM Aggressive Hybrid Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
NJ ELSS Tax Saver Scheme Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
Listing Date
15 Apr, 2019(6 Years,
2 days)
Chairperson NameAmeera Sushil Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
